MENLO PARK, Calif.,
June 14, 2017 /PRNewswire/ --
BioPharmX Corporation (NYSE MKT: BPMX), a specialty pharmaceutical
company focusing on dermatology, presented results of a three (3)
arm preclinical study comparing BPX-01 topical hydrophilic
formulation of minocycline, lipophilic minocycline formulation and
oral minocyline.
The findings were presented in a poster entitled
"Effectiveness and Safety of a Topical Hydrophilic Minocycline
Compared to a Topical Lipophilic Minocycline." The poster
was presented by BioPharmX Senior Director of Preclinical Drug
Development, Usha Nagavarapu, Ph.D., at The Westin Copely Place in
Boston, MA on Tuesday. More
information and details of the poster can be found on the company's
website.
"The study reinforces the efficient penetration and lack of
systemic exposure that the hydrophilic BPX-01 may offer over both
lipophilic minocycline formulations and oral minocycline."
said Kin F. Chan, Ph.D., executive vice president of research and
technology at BioPharmX. "BPX-01 delivered minocycline to the
pilosebaceous unit where acne resides and could not be traced in
plasma."
BioPharmX recently completed a phase 2b clinical study. The data
showed BPX-01 2% reduced the number of inflammatory lesions in acne
patients by 59% (versus 44% in vehicle) with no serious
drug-related side effects, and suggested it may also lessen the
severity of lesions. The company plans to begin its phase 3
research later this year.
The American Academy of Dermatology calls acne the "most common
skin condition in the United States," affecting up to 50 million
Americans. The disease can cause permanent scarring, low
self-esteem, depression and anxiety.
About BioPharmX® Corporation
BioPharmX
Corporation (NYSE MKT: BPMX) is a Silicon Valley-based specialty
pharmaceutical company, which seeks to provide products through
proprietary platform technologies for prescription,
over-the-counter (OTC), and supplement applications in the health
and wellness markets, including dermatology and women's health. To
learn more about BioPharmX, visit www.BioPharmX.com.
Forward-Looking Statements
The information in this
press release contains forward-looking statements and information
within the meaning of Section 27A of the Securities Act of 1933, as
amended, and Section 21E of the Securities Exchange Act of 1934, as
amended, which are subject to the "safe harbor" created by those
sections. This press release contains forward-looking statements
about the company's expectations, plans, intentions, and
strategies, including, but not limited to, statements regarding the
effectiveness of BPX-01 and the successful advancement of the
company's product candidate. These forward-looking statements may
be identified by words such as "plan," "expect," "anticipate,"
"believe" or similar expressions that are intended to identify such
forward-looking statements.
These forward-looking statements involve risks and
uncertainties, as well as assumptions, which, if they do not fully
materialize or prove incorrect, could cause our results to differ
materially from those expressed or implied by such forward-looking
statements. The risks and uncertainties include those described in
the company's filings with the Securities and Exchange Commission,
including our annual report on Form 10-K for the period
ended Jan. 31, 2017. Given these risks and uncertainties, you
are cautioned not to place undue reliance on such forward-looking
statements. The forward-looking statements included in this news
release are made only as of the date hereof, and the company
undertakes no obligation to publicly update or revise any
forward-looking statements, whether as a result of new information,
future events or otherwise, except as may be required under
applicable securities law.
BioPharmX is a registered trademark of BioPharmX, Inc.
To view the original version on PR Newswire,
visit:http://www.prnewswire.com/news-releases/biopharmx-invited-to-present-at-world-preclinical-congress-300473676.html
SOURCE BioPharmX Corporation